

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of the claims in this application.

LISTING OF CLAIMS:

1. (Currently amended) A composition for the inhibition of tumorigenesis comprising a pharmaceutical carrier and an antisense nucleic acid comprising at least ~~[[15]]~~ 100 nucleotides hybridizable in a cell to at least a portion of an RNA transcript of a Nr-CAM gene of SEQ ID NO: 1 in an amount effective to inhibit tumorigenesis by inhibiting hyperproliferation of a human tumor cell having high Nr-CAM expression.

2. (Canceled)

3. (Currently amended) A method of inhibiting proliferation of a human tumor cell overexpressing Nr-CAM in a subject comprising administering locally to the subject an effective amount of a Nr-CAM antisense nucleic acid comprising ~~at least 15 nucleotides that inhibits Nr-CAM expression, wherein the Nr-CAM antisense nucleic acid is hybridizable in the cell to at least a portion of a RNA transcript of the Nr-CAM gene~~ the complement of nucleotides 119 to 1434 of SEQ. ID. NO.: 1; wherein the tumor cell comprises a glioblastoma, a glioma, an astrocytoma, or an oligodendroglioma.

4. (Canceled)

5. (Canceled)

6. (Original) The method according to claim 3 in which the subject is a human.

7. (Canceled)

8. (Currently amended) The method according to claim [[7 ]] 3 in which the glioblastoma is glioblastoma multiforme.

9-21. (Canceled)

22. (Previously presented) The composition of claim 1, wherein the composition is formulated as a liquid.

23. (Canceled)

24. (Currently amended) The method of claim [[23]] 3, wherein the local administration is by direct injection.

25. (Currently amended) The method of claim [[4]] 24, wherein the Nr-CAM antisense nucleic acid is administered locally by direct injection at the site or former site of [[a]] the tumor.

26. (Previously presented) The method of claim 25, wherein the administration is intratumoral.

27.-30. (Canceled)

31. (Currently amended) An isolated nucleic acid comprising at least [[15]] 100 nucleotides, the isolated nucleic acid hybridizable, under highly stringent conditions comprising hybridization in an aqueous solution containing 6X SSC at 65° C, to at least a portion of a messenger RNA having SEQ ID NO: 1 and encoding human Nr-CAM, wherein the oligonucleotide inhibits the expression of Nr-CAM in a tumor cell.

32-33. (Canceled)

34. (New) The composition of claim 1, wherein the antisense nucleic acid comprises the complement of nucleotides 119 to 1434 of SEQ ID NO: 1.

35. (New) The composition of claim 1, wherein the antisense nucleic acid comprises the complement of nucleotides 1410 to 2746 of SEQ ID NO: 1.